tiprankstipranks
Trending News
More News >
Fate Therapeutics (FATE)
NASDAQ:FATE
US Market

Fate Therapeutics (FATE) Stock Forecast & Price Target

Compare
1,189 Followers
See the Price Targets and Ratings of:

FATE Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
4 Buy
9 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Fate
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FATE Stock 12 Month Forecast

Average Price Target

$5.15
▲(322.13%Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $5.15 with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 322.13% change from the last price of $1.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,2.0676923076923077,2.8953846153846152,3.723076923076923,4.550769230769231,5.378461538461539,6.206153846153846,7.033846153846154,7.861538461538462,8.68923076923077,9.516923076923078,10.344615384615386,11.172307692307692,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.540769230769231,1.8415384615384616,2.1423076923076922,2.443076923076923,2.743846153846154,3.0446153846153847,3.3453846153846154,3.6461538461538465,3.9469230769230768,4.247692307692308,4.548461538461539,4.849230769230769,{"y":5.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.2984615384615386,1.356923076923077,1.4153846153846155,1.4738461538461538,1.5323076923076924,1.5907692307692307,1.6492307692307693,1.7076923076923076,1.7661538461538462,1.8246153846153845,1.883076923076923,1.9415384615384617,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.69,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12.00Average Price Target$5.15Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on FATE
TipRanks AITipRanks
Not Ranked
TipRanks
$1
Hold
-18.03%
Downside
Reiterated
05/20/25
Fate Therapeutics has significant financial challenges, with persistent losses and negative cash flow being the primary concerns. While technical indicators suggest mild bullish momentum, the stock's valuation remains difficult due to ongoing losses and no dividend yield. The company's low debt-to-equity ratio offers some financial stability, but strategic changes are essential for long-term viability. Investors should be cautious, given the high beta, indicative of potential volatility.
Wedbush
$5
Hold
309.84%
Upside
Reiterated
05/14/25
Fate Therapeutics (FATE) Receives a Hold from Wedbush
Barclays Analyst forecast on FATE
Peter LawsonBarclays
Barclays
$10$2
Buy
63.93%
Upside
Reiterated
05/14/25
Barclays Reaffirms Their Buy Rating on Fate Therapeutics (FATE)
Oppenheimer Analyst forecast on FATE
Matthew BieglerOppenheimer
Oppenheimer
Hold
Reiterated
05/14/25
Oppenheimer Sticks to Its Hold Rating for Fate Therapeutics (FATE)
Robert W. Baird Analyst forecast on FATE
Jack AllenRobert W. Baird
Robert W. Baird
$5$4
Hold
227.87%
Upside
Reiterated
05/14/25
Fate Therapeutics (FATE) PT Lowered to $4 at BairdBaird analyst Jack Allen lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $4.00 (from $5.00) while maintaining a Neutral rating.
Needham Analyst forecast on FATE
Gil BlumNeedham
Needham
Hold
Reiterated
05/14/25
Needham Remains a Hold on Fate Therapeutics (FATE)
Leerink Partners Analyst forecast on FATE
Daina GrayboschLeerink Partners
Leerink Partners
$12
Buy
883.61%
Upside
Reiterated
05/14/25
Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion
Wells Fargo Analyst forecast on FATE
Yanan ZhuWells Fargo
Wells Fargo
$4
Hold
227.87%
Upside
Reiterated
05/13/25
Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
TD Cowen
Hold
Reiterated
05/13/25
TD Cowen Remains a Hold on Fate Therapeutics (FATE)
Bank of America Securities Analyst forecast on FATE
Tazeen AhmadBank of America Securities
Bank of America Securities
$3$2.5
Hold
104.92%
Upside
Reiterated
03/07/25
Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)
Jefferies Analyst forecast on FATE
Michael YeeJefferies
Jefferies
$10$8
Buy
555.74%
Upside
Reiterated
03/06/25
Fate Therapeutics (FATE) PT Lowered to $8 at JefferiesJefferies analyst Michael Yee lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $10.00) while maintaining a Buy rating.
Morgan Stanley Analyst forecast on FATE
Michael UlzMorgan Stanley
Morgan Stanley
$5
Hold
309.84%
Upside
Reiterated
03/06/25
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties
Stifel Nicolaus Analyst forecast on FATE
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$5$3
Hold
145.90%
Upside
Reiterated
03/06/25
Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)We remain Hold-rated following the company's 4Q24 update; TP to $3/share.
Piper Sandler Analyst forecast on FATE
Edward TenthoffPiper Sandler
Piper Sandler
$6
Buy
391.80%
Upside
Reiterated
03/06/25
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), ALX Oncology Holdings (NASDAQ: ALXO) and Elicio Therapeutics (NASDAQ: ELTX)
H.C. Wainwright Analyst forecast on FATE
Robert BurnsH.C. Wainwright
H.C. Wainwright
$5
Hold
309.84%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on FATE
TipRanks AITipRanks
Not Ranked
TipRanks
$1
Hold
-18.03%
Downside
Reiterated
05/20/25
Fate Therapeutics has significant financial challenges, with persistent losses and negative cash flow being the primary concerns. While technical indicators suggest mild bullish momentum, the stock's valuation remains difficult due to ongoing losses and no dividend yield. The company's low debt-to-equity ratio offers some financial stability, but strategic changes are essential for long-term viability. Investors should be cautious, given the high beta, indicative of potential volatility.
Wedbush
$5
Hold
309.84%
Upside
Reiterated
05/14/25
Fate Therapeutics (FATE) Receives a Hold from Wedbush
Barclays Analyst forecast on FATE
Peter LawsonBarclays
Barclays
$10$2
Buy
63.93%
Upside
Reiterated
05/14/25
Barclays Reaffirms Their Buy Rating on Fate Therapeutics (FATE)
Oppenheimer Analyst forecast on FATE
Matthew BieglerOppenheimer
Oppenheimer
Hold
Reiterated
05/14/25
Oppenheimer Sticks to Its Hold Rating for Fate Therapeutics (FATE)
Robert W. Baird Analyst forecast on FATE
Jack AllenRobert W. Baird
Robert W. Baird
$5$4
Hold
227.87%
Upside
Reiterated
05/14/25
Fate Therapeutics (FATE) PT Lowered to $4 at BairdBaird analyst Jack Allen lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $4.00 (from $5.00) while maintaining a Neutral rating.
Needham Analyst forecast on FATE
Gil BlumNeedham
Needham
Hold
Reiterated
05/14/25
Needham Remains a Hold on Fate Therapeutics (FATE)
Leerink Partners Analyst forecast on FATE
Daina GrayboschLeerink Partners
Leerink Partners
$12
Buy
883.61%
Upside
Reiterated
05/14/25
Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion
Wells Fargo Analyst forecast on FATE
Yanan ZhuWells Fargo
Wells Fargo
$4
Hold
227.87%
Upside
Reiterated
05/13/25
Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
TD Cowen
Hold
Reiterated
05/13/25
TD Cowen Remains a Hold on Fate Therapeutics (FATE)
Bank of America Securities Analyst forecast on FATE
Tazeen AhmadBank of America Securities
Bank of America Securities
$3$2.5
Hold
104.92%
Upside
Reiterated
03/07/25
Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)
Jefferies Analyst forecast on FATE
Michael YeeJefferies
Jefferies
$10$8
Buy
555.74%
Upside
Reiterated
03/06/25
Fate Therapeutics (FATE) PT Lowered to $8 at JefferiesJefferies analyst Michael Yee lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $10.00) while maintaining a Buy rating.
Morgan Stanley Analyst forecast on FATE
Michael UlzMorgan Stanley
Morgan Stanley
$5
Hold
309.84%
Upside
Reiterated
03/06/25
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties
Stifel Nicolaus Analyst forecast on FATE
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$5$3
Hold
145.90%
Upside
Reiterated
03/06/25
Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)We remain Hold-rated following the company's 4Q24 update; TP to $3/share.
Piper Sandler Analyst forecast on FATE
Edward TenthoffPiper Sandler
Piper Sandler
$6
Buy
391.80%
Upside
Reiterated
03/06/25
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), ALX Oncology Holdings (NASDAQ: ALXO) and Elicio Therapeutics (NASDAQ: ELTX)
H.C. Wainwright Analyst forecast on FATE
Robert BurnsH.C. Wainwright
H.C. Wainwright
$5
Hold
309.84%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fate Therapeutics

1 Month
xxx
Success Rate
7/18 ratings generated profit
39%
Average Return
-0.87%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.89% of your transactions generating a profit, with an average return of -0.87% per trade.
3 Months
xxx
Success Rate
12/29 ratings generated profit
41%
Average Return
-0.67%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 41.38% of your transactions generating a profit, with an average return of -0.67% per trade.
1 Year
Peter LawsonBarclays
Success Rate
5/18 ratings generated profit
28%
Average Return
-18.54%
reiterated a buy rating 15 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -18.54% per trade.
2 Years
xxx
Success Rate
3/18 ratings generated profit
17%
Average Return
-49.73%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -49.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FATE Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
7
6
4
6
7
Buy
3
2
0
0
0
Hold
23
14
2
9
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
22
6
15
22
In the current month, FATE has received 7 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. FATE average Analyst price target in the past 3 months is 5.15.
Each month's total comprises the sum of three months' worth of ratings.

FATE Financial Forecast

FATE Earnings Forecast

Next quarter’s earnings estimate for FATE is -$0.34 with a range of -$0.42 to -$0.27. The previous quarter’s EPS was -$0.32. FATE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.86% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
Next quarter’s earnings estimate for FATE is -$0.34 with a range of -$0.42 to -$0.27. The previous quarter’s EPS was -$0.32. FATE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.86% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.

FATE Sales Forecast

Next quarter’s sales forecast for FATE is $1.02M with a range of $0.00 to $3.40M. The previous quarter’s sales results were $1.63M. FATE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 56.25% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
Next quarter’s sales forecast for FATE is $1.02M with a range of $0.00 to $3.40M. The previous quarter’s sales results were $1.63M. FATE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 56.25% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.

FATE Stock Forecast FAQ

What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics’s 12-month average price target is 5.15.
    What is FATE’s upside potential, based on the analysts’ average price target?
    Fate Therapeutics has 322.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FATE a Buy, Sell or Hold?
          Fate Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Fate Therapeutics’s price target?
            The average price target for Fate Therapeutics is 5.15. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $12.00 ,the lowest forecast is $2.00. The average price target represents 322.13% Increase from the current price of $1.22.
              What do analysts say about Fate Therapeutics?
              Fate Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of FATE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis